-
Jubilant Biosys expands collaboration with Sanofi for the CNS treatment area
pharmafocusasia
February 15, 2019
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, today announced a new integrated collaboration with Sanofi for drug discovery for the CNS treatment area....
-
Sanofi Appoints Chief Digital Officer
americanpharmaceuticalreview
February 13, 2019
Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer.....
-
Regeneron and Sanofi cut US list price of Praluent
pharmaceutical-technology
February 13, 2019
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%....
-
Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 study
fiercepharma
January 30, 2019
It’s no secret Sanofi has had trouble with its world-first dengue vaccine, Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
-
NHS faces uphill battle in prevention – survey
pharmaphorum
January 22, 2019
A new survey has revealed confusion amongst the UK public on how to maintain a healthy lifestyle, suggesting the NHS has a long way to go to meet its goal of more disease prevention.
-
Sanofi-Lexicon diabetes drug gets split verdict from FDA panel
pharmaceutical-technology
January 21, 2019
Sanofi and Lexicon Pharmaceuticals have received split decision from an advisory panel to the US Food and Drug Administration (FDA) on whether to recommend diabetes drug Zynquista (sotagliflozin) for approval....
-
Sanofi and Biomunex partner to develop antibody therapeutics
pharmaceutical-technology
January 17, 2019
Sanofi has signed a licensing agreement with French biopharmaceutical firm Biomunex Pharmaceuticals for the development of antibody-based drugs.....
-
Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies
firstwordpharma
January 16, 2019
Biomunex will receive an initial upfront payment and will be eligible to receive further clinical, regulatory and commercial milestone payments. Further financial details were not disclosed.
-
AbSci Establishes New Collaboration with Sanofi
pharmafocusasia
January 11, 2019
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.....
-
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal
expressbpd
January 09, 2019
The two companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while Regeneron retains all rights to its other immuno-oncology discovery and development programmes